文献速递腹部泌尿生殖MR

钆塞酸增强MRI诊断慢性肝病患者肝细胞癌:晚期门静脉期低信号能否作为廓清替代指标

Gadoxetic acid-enhanced MRI for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: can hypointensity on the late portal venous phase be used as an alternative to washout?
PubMed 文献 · Abdom Radiol (NY) · 2020-01-01

回顾性分析97例慢性肝病高危患者共115个肝脏病灶,比较以常规门静脉期(60秒)与常规门静脉期和/或晚期门静脉期(平均99.9±9.1秒)低信号作为廓清标准的诊断效能。以晚期门静脉期低信号作为廓清可显著提高肝细胞癌诊断敏感度(74.4% vs 54.9%,P<0.001),特异度无显著下降(84.8% vs 90.9%,P=0.145)。

要点

  • 晚期门静脉期低信号作为廓清标准使肝细胞癌诊断敏感度从54.9%提高至74.4%。
  • 采用晚期门静脉期低信号后特异度从90.9%降至84.8%,差异无统计学意义(P=0.145)。
  • 82个肝细胞癌中晚期门静脉期低信号出现率84.1%,高于常规门静脉期的64.6%(P<0.001)。

关键影像表现/征象

  • 82个肝细胞癌中,晚期门静脉期低信号出现频率为84.1%(69/82),高于常规门静脉期的64.6%(53/82),差异有统计学意义(P<0.001)。
  • 33个非肝细胞癌病灶中,晚期门静脉期低信号出现频率为39.4%(13/33),常规门静脉期为33.3%(11/33),差异无统计学意义(P=0.500)。
  • 33个非肝细胞癌病灶中有2个为混合型肝细胞癌-胆管癌,其晚期门静脉期较常规门静脉期出现额外低信号。

诊断标准与关键数值

  • 标准1:动脉期高强化且常规门静脉期相对于周围肝实质低信号,诊断肝细胞癌的敏感度为54.9%(45/82),特异度为90.9%(30/33)。
  • 标准2:动脉期高强化且常规门静脉期和/或晚期门静脉期相对于周围肝实质低信号,诊断肝细胞癌的敏感度为74.4%(61/82),特异度为84.8%(28/33)。
  • 标准2较标准1敏感度提高(74.4% vs 54.9%,P<0.001),特异度降低但差异无统计学意义(84.8% vs 90.9%,P=0.145)。

临床应用与阅片要点

  • 在慢性肝病患者钆塞酸增强MRI阅片时,可将晚期门静脉期(约90-119秒)低信号作为廓清的替代标准以提高肝细胞癌检出敏感度。
  • 采用该标准时需注意特异度相对降低(84.8% vs 90.9%),非肝细胞癌病灶中混合型肝细胞癌-胆管癌也可在晚期门静脉期出现低信号。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To investigate the added value of considering hypointensity on late portal venous phase (LPVP) images as washout for diagnosis of hepatocellular carcinoma (HCC) using gadoxetic acid-enhanced MRI (Gd-EOB-MRI) in patients with chronic liver disease (CLD).

METHODS: This retrospective study comprised 97 patients at high risk for HCC who underwent Gd-EOB-MRI including unenhanced, multi-arterial phase, conventional portal venous phase (CPVP, 60 s), and LPVP (mean, 99.9 ± 9.1 s; range, 90-119 s) images. A total of 115 hepatic lesions were identified by histopathological or clinical diagnosis. Three independent radiologists assessed the MRI images by consensus. Diagnosis of HCC was made using criteria of arterial hyperenhancement and hypointensity relative to the surrounding liver parenchyma (1) on CPVP or (2) on CPVP and/or LPVP images. The generalized estimating equation was used to compare diagnostic performance for HCC between Criterion 1 and 2.

RESULTS: In 82 HCCs, the frequency of hypointensity differed significantly between the CPVP and LPVP images (64.6% [53/82] vs. 84.1% [69/82], P < 0.001). Among 33 non-HCCs, two cHCC-CCs showed additional hypointensity on LPVP than CPVP images (33.3% [11/33] vs. 39.4% [13/33], P = 0.500). Criterion 2 provided significantly greater sensitivity for diagnosing HCC than Criterion 1 (54.9% [45/82] vs. 74.4% [61/82], P < 0.001), with relatively little reduction in specificity (90.9% [30/33] vs. 84.8% [28/33], P = 0.145).

CONCLUSION: Additional use of LPVP hypointensity as washout could significantly improve sensitivity for HCC diagnosis when utilizing Gd-EOB-MRI in patients with CLD, without a significant decrease in specificity.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Baek KA, Kim SS, Shin HC, et al. Gadoxetic acid-enhanced MRI for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: can hypointensity on the late portal venous phase be used as an alternative to washout? Abdom Radiol (NY). 2020. PMID: 32382820. doi:10.1007/s00261-020-02553-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。